
Bernard Marini, PharmD, BCOP, gives an overview of selecting the most effective, safest, and most cost-effective acute myeloid leukemia treatments for patients.
Bernard Marini, PharmD, BCOP, gives an overview of selecting the most effective, safest, and most cost-effective acute myeloid leukemia treatments for patients.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Top news of the week from Specialty Pharmacy Times.
Top news of the day from across the health care landscape.
Study shows the importance of screening and treatment for depression, especially among patients with HIV since there has been an increase in life expectancy due to antiretroviral therapy.
Top news of the day from across the health care landscape.
Accreditation helps pharmaceutical manufacturers narrow the potential pharmacies it may include in a specialty network offering.
Top news of the day from across the health care landscape.
Study finds that surgery was associated with a 44% increased chance of survival in patients with breast cancer, assuming the majority also had systemic treatment.
Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses key trials in prostate cancer research.
Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed the recent updates to the American Cancer Society's screening guidelines for colorectal cancer.
Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, provides an overview of the evolving treatment paradigm for chronic lymphocytic leukemia.
Riluzole oral film is a novel formulation of riluzole, which is an adjuvant therapy for amyotrophic lateral sclerosis.
Study finds a dramatic difference between guidelines for tests such as mammograms and colon cancer screenings between the United Kingdom and the United States.
Top news of the day from across the health care landscape.
Glecaprevir/pibrentasvir (G/P) plus sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.
Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, discusses the importance of the pharmacist's role in the management of chronic lymphocytic leukemia treatments.
Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, explains how pharmacists can counsel patients about risk factors for colorectal cancer and reduction strategies.
Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed emerging trends in oncology care.
In this clip, Bernard Marini, PharmD, BCOP, inpatient hematology specialist at the University of Michigan, discusses how IDH inhibitors like ivosidenib and enasidenib fit into the treatment landscape for patients with relapsed or refractory acute myeloid leukemia.
Each member of the specialty pharmacy care team is an essential component in influencing and ensuring positive outcomes of therapy.
Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses the challenges associated with establishing or expanding specialty pharmacy services within an institution.
Top news of the day from across the health care landscape.
Official with the FDA today granted accelerated approval to erdafitinib (Balversa, Janssen) for adult patients with locally advanced or metastatic bladder cancer.
The expanded first-line indication makes pembrolizumab (Keytruda) monotherapy an option for more patients with non-small cell lung cancer.
Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Top news of the day from across the health care landscape.
There are currently firms working to use artificial intelligence in hopes that it could contribute to minimizing the impact of the opioid epidemic.
Cytomegalovirus may contribute to faster cystic fibrosis progression, but further studies are warranted to confirm these findings.